Multiple experiments containing the ALK kinase activity, phosphoproteomic analysis of ALK-positive lung cancer cells, and kinase substrate-enrichment analysis unequivocally ascertained that gilteritinib directly inhibited the growth of ALK-rearranged human NSCLC cells and further overcame lorlatinib resistance to the double mutant ALK I1171N/F1174I (Mizuta et al., 2021). This evidence concerns the gene ALK and lung carcinoma.